Work

A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma

Year: 2018

Type: article

Study design: Clinical Trial

Source: International Journal of Hematology

DOI: 10.1007/s12185-018-2468-5

Authors: Shira Dinner, Tamara J. Dunn, Elizabeth Price, Steven E. Coutré, Jason Gotlib, Caroline Berube, Gregory P. Kaufman, Bruno C. Medeiros, Michaela Liedtke

Institutions: Northwestern University, Stanford Medicine, Stanford University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Celgene

OpenAlex ID: W2804158423

FWCI: 0.152

Cites: 27

Cited by: 1

Related to: 10